Trastuzumab deruxtecan
About
Therapy type: Targeted therapy
Therapy strategy: HER2 inhibition
Mappings
NCI Thesaurus: Trastuzumab Deruxtecan (coding:ncit:C128799)
RxNorm: trastuzumab deruxtecan (coding:rxcui:2267582, coding:omop:3666979)
SNOMED: Trastuzumab deruxtecan (coding:sctid:838469001, coding:omop:37498192)
Therapeutic response
Precision oncology relationships for therapeutic response involving this therapy.
| Organizations | Biomarkers | Cancer types | Therapies | |
|---|---|---|---|---|
| FDA (1) HC (2) | HER2-positive | Invasive Breast Carcinoma | Trastuzumab deruxtecan | |
| FDA (1) HC (1) | HER2-low | Invasive Breast Carcinoma | Trastuzumab deruxtecan | |
| FDA (1) | ERBB2 activating variants | Non-Small Cell Lung Cancer | Trastuzumab deruxtecan | |
| FDA (1) HC (1) | HER2-positive | Adenocarcinoma of the Gastroesophageal Junction | Trastuzumab deruxtecan | |
| FDA (1) HC (1) | HER2-positive | Any solid tumor | Trastuzumab deruxtecan | |
| FDA (1) | HER2-positive | Invasive Breast Carcinoma | Pertuzumab, Trastuzumab deruxtecan |